Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | RTX-240 |
Trade Name | |
Synonyms | RTX 240|RTX240 |
Drug Descriptions |
RTX-240 is a therapy comprised of allogeneic red blood cells (RBCs) engineered to express a fusion protein consisting of the cytokine IL-15 and the IL-15 receptor alpha and TNFSF9 (4-1BBL), which may lead to activation of immune cells and antibody-dependent cell mediated cytotoxicity (ADCC) induced tumor cell killing (NCI Drug Dictionary; Journal for ImmunoTherapy of Cancer 2020;8). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C172990 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
RTX-240 | RTX-240 | 0 | 1 |